| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,398,000 |
| Market
Cap: |
389.26(M) |
| Last
Volume: |
1,040,465 |
Avg
Vol: |
716,466 |
| 52
Week Range: |
$3.38 - $6.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 803 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
121,098 |
133,534 |
375,216 |
| Total Sell Value |
$0 |
$513,345 |
$588,387 |
$2,607,605 |
| Total People Sold |
0 |
5 |
6 |
6 |
| Total Sell Transactions |
0 |
10 |
13 |
31 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Williams Timothy |
SVP & General Counsel |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
87,425 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,294,579 |
|
- |
|
| Wijkstrom Joakim |
SVP, Chief Marketing Officer |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
60,000 |
|
- |
|
| Jones Aranthan Ii |
Chief Corp. Affairs Officer |
• – – |
2020-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
90,000 |
|
- |
|
| Reverberi Gian Piero |
SVP & Chief Commercial Officer |
• – – |
2020-01-02 |
4 |
S |
$16.06 |
$18,551 |
D/D |
(1,155) |
166,834 |
|
28% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2020-01-02 |
4 |
S |
$15.93 |
$64,021 |
D/D |
(4,020) |
147,231 |
|
28% |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2020-01-02 |
4 |
S |
$16.00 |
$151,493 |
D/D |
(9,467) |
1,234,579 |
|
28% |
|
| Kelly James Patrick |
EVP & Chief Financial Officer |
• – – |
2020-01-02 |
4 |
S |
$15.94 |
$64,086 |
D/D |
(4,020) |
205,726 |
|
28% |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-12-12 |
4 |
S |
$16.98 |
$1,189,351 |
D/D |
(70,036) |
1,244,046 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-12-12 |
4 |
OE |
$10.65 |
$913,781 |
D/D |
85,801 |
1,314,082 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-12-11 |
4 |
S |
$16.92 |
$1,224,377 |
D/D |
(72,373) |
1,228,281 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-12-11 |
4 |
OE |
$10.65 |
$949,969 |
D/D |
89,199 |
1,300,654 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2019-08-26 |
4 |
S |
$14.85 |
$222,750 |
D/D |
(15,000) |
35,770 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2019-08-26 |
4 |
OE |
$14.78 |
$221,700 |
D/D |
15,000 |
50,770 |
|
- |
|
| Jones Aranthan Ii |
Chief Corp. Affairs OfficerOff |
• – – |
2019-08-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
60,000 |
|
- |
|
| Wijkstrom Joakim |
SVP, Chief Marketing Officer |
• – – |
2019-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2019-08-14 |
4 |
S |
$14.69 |
$37,829 |
D/D |
(2,575) |
57,425 |
|
- |
|
| Cola Michael F |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,000 |
|
- |
|
| Chrousos Phaedra |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
35,770 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
30,000 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-05-21 |
4 |
S |
$15.34 |
$1,117,951 |
D/D |
(72,872) |
1,211,455 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-05-21 |
4 |
OE |
$12.55 |
$991,688 |
D/D |
79,019 |
1,284,327 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-05-20 |
4 |
S |
$15.12 |
$1,019,084 |
D/D |
(67,418) |
1,205,308 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEO |
• • – |
2019-05-20 |
4 |
OE |
$12.55 |
$923,780 |
D/D |
73,608 |
1,272,726 |
|
- |
|
277 Records found
|
|
Page 7 of 12 |
|
|
0.01 (0.16%) 
